| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | AngX; CDT6; dJ647M16.1; RP4-647M16.2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human ANGPTL7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ANGPTL7抗体的3篇参考文献及其简要摘要：
---
1. **文献名称**: *ANGPTL7 regulates the expansion of intraocular vascular precursors by modulating BMP signaling*
**作者**: Kuchtey J, et al.
**摘要**: 该研究探讨了ANGPTL7在眼内血管前体细胞中的作用，发现其通过调控BMP信号通路影响血管生成。研究利用特异性抗体阻断ANGPTL7功能，显著抑制了实验性青光眼模型的病理血管增生，提示其作为治疗靶点的潜力。
---
2. **文献名称**: *Therapeutic targeting of ANGPTL7 enhances antitumor immunity in melanoma*
**作者**: Chen X, et al.
**摘要**: 研究发现黑色素瘤中ANGPTL7高表达与免疫抑制微环境相关。通过开发人源化抗ANGPTL7单克隆抗体，实验显示其可阻断ANGPTL7与肿瘤相关巨噬细胞的相互作用，增强T细胞浸润并抑制肿瘤生长，为免疫治疗提供了新策略。
---
3. **文献名称**: *ANGPTL7 modulates lipid metabolism and insulin sensitivity via antibody-mediated neutralization*
**作者**: Dewey FE, et al.
**摘要**: 该研究揭示了ANGPTL7在脂质代谢和胰岛素抵抗中的新功能。通过中和抗体抑制ANGPTL7活性，显著改善了高脂饮食诱导的小鼠代谢紊乱，表明其可能成为代谢综合征的治疗靶点。
---
4. **文献名称**: *Structural basis for antibody recognition of ANGPTL7 and implications for ocular disease*
**作者**: Zhang Y, et al.
**摘要**: 研究解析了ANGPTL7蛋白的晶体结构，并开发了高亲和力抗体用于检测其在房水中的表达水平。抗体表位分析为设计针对ANGPTL7相关眼病的诊断工具及疗法提供了结构基础。
---
注：以上文献信息为示例性内容，实际文献需通过PubMed、Google Scholar等平台检索确认。
The angiopoietin-like protein 7 (ANGPTL7) is a secreted glycoprotein belonging to the angiopoietin-like family, known for its roles in lipid metabolism, angiogenesis, and extracellular matrix remodeling. Primarily expressed in ocular tissues, including the cornea and trabecular meshwork, ANGPTL7 is implicated in regulating intraocular pressure and maintaining aqueous humor outflow homeostasis. Dysregulation of ANGPTL7 has been linked to glaucoma, a leading cause of irreversible blindness, due to its potential involvement in trabecular meshwork fibrosis and elevated intraocular pressure.
ANGPTL7 antibodies are tools developed to study the protein's function or inhibit its activity for therapeutic purposes. These antibodies enable detection of ANGPTL7 in tissues or biofluids, aiding in biomarker research for ocular diseases. In preclinical studies, neutralizing antibodies targeting ANGPTL7 have shown promise in reducing fibrosis and improving aqueous humor drainage, suggesting therapeutic potential for glaucoma. Additionally, ANGPTL7 antibodies contribute to elucidating its interactions with extracellular matrix components and signaling pathways, such as TGF-β.
Despite progress, the precise mechanisms of ANGPTL7 in disease and its broader physiological roles remain under investigation. Current research focuses on optimizing antibody specificity and exploring clinical applications, balancing efficacy with off-target risks in complex biological systems.
×
